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Abstract Phosducin-like protein (PhLP) has recently been 
identified as a ubiquitous inhibitor of G-protein βγ-subunit 
(G|i,,)-mc'diated signaling, with an affinity about 5-fold lower 
than that of phosducin. The GßY binding site of phosducin has 
been suggested to be contained in its N-terminus. A region 
corresponding to this N-terminus is lacking in PhLP, suggesting 
that PhLP must utilize a different mode of GßY binding. To map 
the G|iy binding site in PhLP, a series of deletion mutants were 
constructed, expressed in E. coli as glutathione 5-transferasc 
(GST) fusion proteins, and the purified fusion proteins were 
examined for their ability to attenuate G0 GTPase activity. 
Progressive N-terminal truncations of PhLP caused only minor 
reductions in potency, whereas the complementary N-terminal 
PhLP fragments turned out to be inactive. We further identified 
a short C-terminal segment comprising residues 168 to 195 that 
inhibited GQ GTPase activity similar in efficacy and potency to 
full-length PhLP. This C-terminal fragment was also capable of 
antagonizing a second Gp,-mediated function, the enhancement 
of rhodopsin phosphorylation by the ß-adrenergic receptor 
kinase. Taken together, these data indicate that PhLP interacts 
with Gßy via a short C-terminal binding site which is distinct from 
that identified previously in phosducin. 
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1. Introduction 
Heterotrimeric G-proteins with their α-, β- and γ-subunits 
relay signals from seven-transmembrane-helix receptors to ef-
fector molecules. Upon agonist binding, receptors stimulate 
G-proteins to exchange GDP for GTP which leads to disso-
ciation of GTP-liganded oc-subunits from tightly bound βγ-
subunit complexes (for reviews, see [1-3]). For a long time, 
G a was considered to be the principal mediator of G-protein 
function. However, over the past years it has become evident 
that GßT-subunits have multiple signaling functions of their 
own (reviewed in [4-6]). The growing list of GßY-regulated 
effectors includes adenylyl cyclases, phospholipases C-ß and 
A2, several ion channels and kinases, such as phosphoinosi-
tide-3-kinase and mitogen-activated kinase. In addition, GßY-
subunits provide a membrane anchor and an activator for the 
ß-adrenergic receptor kinase (ßARK) which enables the ki-
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nase to translocate from the cytosol to its substrate receptors 
in the cell membrane [7-9]. 
Phosducin is a Gßy-binding protein, for which no effector 
function has been reported so far. It is a cytosolic phospho-
protein that is most abundantly expressed in retinal rods [10] 
and the pineal gland [11], but has also been detected in many 
other tissues [12,13]. Phosducin binds to GßT dimers with high 
affinity and can thereby inhibit G-protein-mediated signaling 
[12,14,15]. Phosducin has also been demonstrated to compete 
with ßARK for GßY and thus to attenuate ßARK-catalyzed 
receptor phosphorylation [16,17]. 
GßT-regulated proteins have recently attracted much interest 
with respect to identifying common Gßy-binding motifs. In the 
case of ßARK and the Ras guanine nucleotide releasing fac-
tor, the Gßy-binding region has been mapped to the C-termi-
nus of their pleckstrin homology domain including extensions 
beyond it [18,19]. Furthermore, several unrelated GßY effectors 
have been found to share a common sequence, Gln/Asn-X-X-
Glu/Asp-Arg/Lys, which has been proposed to be an impor-
tant determinant for receiving signals from GßY [20]. In phos-
ducin, which does not contain the structural motifs men-
tioned, the Gßy-binding domain has been assigned by two 
independent studies to the N-terminal 105 [21] or 63 amino 
acids [22], respectively. 
Recently, the cDNAs of two splice variants of a phosducin-
like protein have been cloned from rat brain which show a 
broad tissue distribution [23]. The splice variants differ in the 
length of their N-termini. The short variant, hereafter referred 
to as PhLP, lacks most of the N-terminal region which in 
phosducin has been postulated to contain the Gßy-binding 
site [21,22]. However, PhLP, when expressed and purified as 
a recombinant protein, did show GßY binding in a variety of 
assays [24]: it inhibited the GTPase activity of G0 as well as 
the Gßy-subunit-dependent ADP-ribosylation of Ga o by per-
tussis toxin, and it antagonized the effects of Gßy-subunits on 
the phosphorylation of rhodopsin by ßARK. In all these as-
says, the affinity of PhLP was only 5-fold lower than that of 
phosducin. Therefore, PhLP appears to have its own mode of 
Gßy binding. The present study was undertaken to identify 
this Gßy-binding site. 
2. Materials and methods 
2.1. Construction, expression and purification of GST fusion proteins 
PhLP wild-type and deletion mutant cDNAs were amplified by 
polymerase chain reactions using the complete coding sequence of 
PhLP as a template [24] and 5' and 3' primers that contained BamHl 
and EcoRl sites, respectively. The various cDNA fragments were li-
gated in-frame downstream from the GST coding region and the 
thrombin cleavage site of the fusion vector pGEX-ΙλΤ (Pharmacia). 
All cDNA constructs were confirmed by automated sequencing and 
were introduced into E. coli strain BL21(DE3)pLysS. Following in-
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duction with 0.1 mM isopropyl-ß-D-thiogalactoside for 2.5 h at 25°C, 
the cell pellets were disrupted in a buffer containing 50 mM Tris-HCl, 
pH 7.8, 20 mM EDTA and 0.1% Triton X-100. DNA was precipitated 
with 2% streptomycin sulfate followed by centrifugation for 30 min at 
50 000 X g. The clear supernatant was applied on a glutathione agarose 
(Fluka) column and washed with 20 mM Tris-HCl, pH 7.6, 200 mM 
NaCl, 1 mM EDTA and 1 mM DTT. The GST fusion proteins were 
eluted with washing buffer containing 10 mM glutathione (Fluka), pH 
7.6, and were dialyzed against 10 mM Tris-HCl, pH 7.6, 1 mM DTT 
at 4°C. The fractions were concentrated in Centricon devices (Ami-
con), glycerol was added to a final concentration of 15%, and samples 
were stored at -80°C. 
2.2. Purification of thrombin-cleaved fusion proteins 
GST fusion protein bound to glutathione agarose beads (Fluka) 
was cleaved with 20 units of thrombin (Sigma) per 5 mg fusion pro-
tein in a buffer containing 20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 
2.5 mM CaCl2, 1 mM DTT. Following 3 h of incubation at room 
temperature, cleaved PhLP and thrombin were eluted. Contaminating 
thrombin was removed by binding to SP-Sepharose (Pharmacia). 
Fractions of unbound PhLP were desalted, concentrated and stored 
as described in Section 2.1. 
2.3. Purification of other proteins 
G0 and G-protein βγ-subunits were purified from bovine brain ac-
cording to established procedures [25]. Bovine ßARK was expressed 
in Sf9 cells and purified as described [26]. 
2.4. Protein determination 
The purity of proteins was judged from Coomassie-blue-stained 
polyacrylamide gels and their concentration determined according to 
Bradford [27]. 
2.5. GTPase activity of G0 
G0 was reconstituted into crude soybean phosphatidylcholine vesi-
cles as described [28]. The GTPase activity of 0.1 pmol (1 nM) G0 was 
determined in a volume of 100 μΐ in the presence of 50 μΜ of Mas-7 
(Biomol) as described [12,29]. The effects of fusion proteins containing 
full-length and mutant PhLP were examined at concentrations of 3-
3000 nM. 
2.6. Phosphorylation of rhodopsin 
Urea-treated rod outer segments containing > 95% rhodopsin were 
prepared from bovine retina [30]. 40 pmol rhodopsin was phospho-
rylated in a volume of 40 μΐ using 7.5 nM purified recombinant 
ßARK and 75 nM purified G-protein βγ-subunits as described earlier 
[16]. The C-terminal PhLP fragments were present at 1, 5 and 20 μΜ. 
The incubation was carried out at 30°C for 6 min under bright white 
light. The reaction was stopped, and the samples were analyzed by 
SDS polyacrylamide gel electrophoresis, autoradiography, and Ceren-
kov counting of the excised rhodopsin bands. 
2.7. Data analysis 
Data are presented as means ± S.E.M. of at least three independent 
experiments. Concentration-response curves were fitted to the Hill 
equation by non-linear curve-fitting as described earlier [31] in order 
to obtain estimates for potency (IC50) and efficacy (Imax) of PhLP and 
its deletion constructs. 
3. Results 
In order to map rat PhLP for regions that are involved in 
binding to Gßy we prepared a series of deletion mutants using 
PCR (Fig. 1). Wild-type PhLP and its mutants were expressed 
as GST fusion proteins in E. coli. Following cell disruption 
and centrifugation, fusion proteins were obtained in the super-
natant. Best yields of soluble protein were achieved when 
bacterial expression was induced at 25°C with low concentra-
tions of isopropyl-ß-D-thiogalactoside (0.1 mM) followed by 
lysing the cells with Triton X-100. From the soluble fraction, 
GST fusion proteins were then purified on a glutathione agar-
ose column. The resultant preparations were > 95% pure as 
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Fig. 1. PhLP deletion mutants. Schematic representation of full-
length PhLP and six truncation mutants which were fused to glu-
tathione S-transferase and expressed in E. coli as described in Sec-
tion 2. The scheme depicts the PhLP moieties of the corresponding 
fusion proteins. N-terminal GST affinity tails are not shown. Num-
bers indicate the first and last amino acid residues in each construct 
according to residue positions in wild-type PhLP. 
judged by Coomassie-blue-stained SDS-polyacrylamide gels 
(not shown). 
To examine the ability of the purified PhLP mutants to 
interact with GßY, we first assayed their inhibitory effect on 
G0 function in GTPase assays. In the presence of G-protein 
activators, such as receptors or high concentrations of Mg2+, 
GßT subunits enhance the GTPase activity of Gao. We recon-
stituted G0 purified from bovine brain into phospholipid ve-
sicles and stimulated its GTPase activity with Mas-7, a potent 
analogue of mastoparan which acts on G-proteins in a recep-
tor-mimetic way [32]. In these experiments, 50 μΜ Mas-7 
enhanced G0 GTPase activity about 14-fold. Addition of the 
GST fusion protein containing the entire PhLP inhibited the 
activity by ~ 90% in a concentration-dependent manner (Fig. 
2). Inhibition occurred with an IC50 value of 65 ± 9 nM, which 
is in very good accordance with the value measured for PhLP 
lacking the GST moiety [24]. This suggests that GST when 
linked N-terminally to full-length PhLP does not impair 
PhLP's interaction with GQ. Purified GST alone, used as a 
negative control, displayed no inhibitory activity in this assay 
(data not shown). Fig. 2 summarizes the effects of PhLP mu-
tants that were truncated at their N-terminus. Deletions of the 
first 71 and 142 amino acids (GST fusion proteins of P72-218 
and PI43-218) caused only modest reductions of IC50 values 
by factors ~ 2 and ~ 4, respectively. However, in both cases, 
the maximal inhibition was smaller and reached a level of only 
~70%>. Further N-terminal truncations did not further shift 
the inhibition curves to higher concentrations: GST fusion 
proteins containing the very C-terminus of PhLP (PI68-218) 
or an even shorter stretch lacking the last amino acids of the 
C-terminus (P168-195) still inhibited GQ function potently. 
Maximal inhibition for the latter fusion proteins was ~ 60%. 
For control purposes we tested two PhLP deletion mutants 
that were complementary to the active C-terminal segments. 
The data shown in Fig. 3 illustrate that the two GST fusion 
proteins encompassing the first 142 or 167 amino acids failed 
to attenuate effectively the G0 GTPase reaction. Taken to-
gether, these observations indicate that the C-terminal seg-
ment of PhLP comprising residues 168-195 plays a crucial 
role in binding to G0. 
In order to obtain more direct evidence that the C-terminus 
of PhLP binds to G-protein βγ-subunits, we used an assay 
that did not involve G-protein α-subunits. To this end, we 
measured the enhancement of ßARK-catalyzed rhodopsin 
phosphorylation by Gßy-subunits. In this assay, the Gßy-sub-
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Fig. 2. Inhibition of G0 GTPase activity by GST fusion proteins 
containing full-length and N-terminally truncated PhLP. The 
GTPase activity of 0.1 pmol G0 (1 nM) reconstituted in phosphati-
dylcholine vesicles was determined in the presence of 50 μΜ Mas-7. 
GST-PhLP fusion proteins were present at the indicated concentra-
tions. Values are expressed as % of the GTPase activity in the pres-
ence of Mas-7. Non-linear curve fitting to the Hill equation as de-
scribed [31] gave the following IC50 values: GST-PhLP, 65±9 nM; 
GST-P72-218, 104±2 nM; GST-P143-218, 224±3 nM; GST-P168-
218, 135 ±3 nM; GST-P168-195, 67 ±2 nM. Data are means 
±S.E.M., n = 6. 
units serve as membrane anchors and presumably also as 
activators of ßARK [7-9]. We have reported earlier that 
PhLP inhibits rhodopsin phosphorylation in this assay by 
up to 77 ± 10% with an IC50 value of 600 ± 200 nM [24]. Since 
the GST fusion moiety appeared to perturb these assays (data 
not shown), they were done with the PhLP fragments cleaved 
from GST with thrombin and then purified. The two C-ter-
minal fragments P168-195 and P168-218 both inhibited rho-
dopsin phosphorylation in a concentration-dependent manner 
(Fig. 4) by up to 60% (at 20 μΜ). Half-maximal inhibition 
occurred at ~ 5 μΜ. The efficacy of the two peptides was thus 
very similar to that of the entire PhLP. This confirms the 
notion that the major site of interaction with G-protein βγ-
subunits is contained in the region 168-195 of PhLP. 
4. Discussion 
G-protein βγ-subunits have recently been identified as active 
signal transducers. Their interactions with multiple upstream 
receptors as well as downstream effectors have raised consid-
erable interest in recent years. However, there is no consensus 
regarding the structural or sequence requirements for such 
interactions. In the case of phosducin, two independent stud-
ies have mapped the Gßy-binding domain to the N-terminus 
[21,22], and the N-terminus of phosducin has been proposed 
to contain similarities to the pleckstrin homology domain of 
the ß-adrenergic receptor kinase [21]. Since PhLP is similar to 
phosducin but lacks this N-terminus, it would be expected to 
be devoid of Gßy-binding. However, we have recently ob-
served that PhLP has inhibitory effects in several assays of 
GßY function with an affinity only about 5-fold lower than 
that of phosducin [24]. From these data we concluded that 
the Gßy-binding domain of PhLP is most likely contained in 
its central and C-terminal domains, i.e. the regions showing 
significant similarity to phosducin, but not in its short N-ter-
minus, which is divergent from phosducin. 
In the present study we have mapped this putative Gßy-
binding site to a C-terminal fragment of PhLP comprising 
only 28 amino acids. This short fragment, similar in size to 
a peptide contained in adenylyl cyclase 2 and proposed to 
represent its GßT-binding site [20], has a submicromolar affin-
ity for Gßy and an efficacy in inhibiting the GTPase activity 
of G0 which almost equals that of intact PhLP. We have not 
found any sequence similarity between the region PhLP 168-
195 and this QEHA peptide from adenylyl cyclase 2 (data not 
shown), suggesting that the two GßT-binding sites are different 
in type and presumably also in their mode of interaction with 
Gßy. However, like the QEHA peptide, the PhLP fragment 
not only inhibits the GTPase activity of G0 - which it pre-
sumably does by disturbing the interaction between Ga o and 
Gßy - but also antagonizes the effects of GßY on ßARK. This 
indicates that via a short defined binding site PhLP can inhibit 
several functions of G-protein βγ-subunits. Thus, several pro-
teins appear to be capable of impairing Gßy signalling proper-
ties due to distinct types of Gßy-binding. 
Gaudet et al. have very recently published the crystal struc-
ture of the complex of phosducin with transducin GßY [33]. 
This structure reveals two separate Gßy-binding domains of 
phosducin at its N- and C-terminus, respectively, that bind to 
spatially distinct regions on the GßY surface. Interestingly, the 
C-terminal domain interacts with the outer strands of the 
transducin Gß propeller which are not involved in G a binding. 
Thus, if one assumes a similar structure for PhLP, these re-
sults suggest that the C-terminal peptides of PhLP appear to 
inhibit G0 GTPase activity by an allosteric mechanism rather 
than by competition with G a . 
Taken together, our data indicate that PhLP binds to GßY 
via a site distinct from that identified in earlier mapping stud-
ies with phosducin. This site confers on PhLP high affinity for 
Gßy and the ability to disrupt different Gßy functions. This 
high affinity for GßT together with the fact that PhLP is ex-
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Fig. 3. Lack of effect of C-terminally truncated PhLP variants on 
the GTPase activity of G0. The G0 GTPase activity was determined 
in the presence of 50 μΜ Mas-7 as in Fig. 2. GST fusion proteins 
comprising the N-terminal 142 and 167 amino acid residues of 
PhLP were assayed at increasing concentrations for their interfer-
ence with G0 GTPase function. The plot shows the data obtained in 
comparison with the inhibition caused by the full-length PhLP fu-
sion protein. Data are means ±S.E.M., n = 6. 
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Fig. 4. Inhibition of GpY-enhanced rhodopsin phosphorylation by C-
terminal peptides of PhLP. Rod outer segments (40 pmol rhodop-
sin) were phosphorylated by purified ßARK (7.5 nM) in the pres-
ence of 75 nM Gßy-subunits and varying amounts of the PhLP frag-
ments P168-218 or P168-195, respectively, which lacked the GST 
moiety due to thrombin cleavage (for preparation protocol see Sec-
tion 2.2). A: Autoradiogram with rhodopsin bands phosphorylated 
by ßARK in presence of the indicated components. PhLP peptides 
were applied at a concentration of 20 μΜ. B: Quantitation of rho-
dopsin phosphorylation at increasing PhLP peptide concentrations. 
Phosphate incorporation into rhodopsin in the absence of GßY 
(0.007110.0006 mol phosphate per mol rhodopsin) was set at 0%, 
the corresponding value in the presence of GpY-subunits 
(0.051 ±0.003 mol phosphate per mol rhodopsin) was set at 100%. 
Data are means ± S.E.M., n = 6. 
pressed in many tissues suggests that it may be a major reg-
ulator of G-protein-mediated signalling by hormone and neu-
rotransmitter receptors. 
Acknowledgements: These studies were supported by grants from the 
Deutsche Forschungsgemeinschaft (SFB 176 and SPP GTPasen), and 
the Fonds der Chemischen Industrie. 
References 
[1] Bourne, H.R., Sanders, D.A. and McCormick, F. (1990) Nature 
348, 125-132. 
[2] Hepler, J.R. and Gilman, A.G. (1992) Trends Biochem. Sei. 17, 
383-389. 
[3] Offermanns, S. and Schultz, G. (1994) Naunyn-Schmiedeberg's 
Arch. Pharmacol. 350, 329-338. 
[9: 
[10 
[11 
[i2: 
[is: 
[i4: 
[is: 
[i6: 
[i?: 
[is: 
[19 
[20 
[21 
[22 
[23: 
[24: 
[25: 
[26 
[27' 
[28: 
[29 
[30 
[31 
[32 
[33: 
Birnbaumer, L. (1992) Cell 71, 1069-1072. 
Neer, E.J. (1995) Cell 80, 249-257. 
Müller, S. and Lohse, M.J. (1995) Biochem. Soc. Transact. 23, 
141-148. 
Haga, K. and Haga, T. (1992) J. Biol. Chem. 267, 2222-2227. 
Pitcher, J.A., Inglese, J., Higgins, J.B., Arriza, J.L., Casey, P.J., 
Kim, C , Benovic, J.L., Kwatra, M.M., Caron, M.G. and Lefko-
witz, R.J. (1992) Science 257, 1264-1267. 
Kim, CM., Dion, S.B. and Benovic, J.L. (1993) J. Biol. Chem. 
268, 15412-15418. 
Lee, R.H., Lieberman, B.S. and Lolley, R.N. (1987) Biochemistry 
26, 3983-3990. 
Reig, J.A., Yu, L. and Klein, D.C. (1990) J. Biol. Chem. 265, 
5816-5824. 
Bauer, P.H., Müller, S., Puzicha, M., Pippig, S., Helmreich, 
E.J.M. and Lohse, M.J. (1992) Nature 358, 73-76. 
Danner, S. and Lohse, M.J. (1996) Proc. Natl. Acad. Sei. USA 
93, 10145-10150. 
Lee, R.H., Ting, T.D., Lieberman, B.S., Tobias, D.E., Lolley, 
R.N. and Ho, Y.-K. (1992) J. Biol. Chem. 267, 25104-25112. 
Schulz, K., Danner, S., Bauer, P., Schröder, S. and Lohse, M.J.L. 
(1996) J. Biol. Chem. 271, 22546-22551. 
Hekman, M., Bauer, P.H., Söhlemann, P. and Lohse, M.J. (1994) 
FEBS Lett. 343, 120-124. 
Müller, S., Straub, A., Schröder, S., Bauer, P. and Lohse, M.J. 
(1996) J. Biol. Chem. 271, 11781-11786. 
Koch, W.J., Inglese, J., Stone, W.C. and Lefkowitz, R.J. (1993) 
J. Biol. Chem. 268, 8256-8260. 
Touhara, K., Inglese, J., Pitcher, J.A., Shaw, G. and Lefkowitz, 
R.J. (1994) J. Biol. Chem. 269, 10217-10220. 
Chen, J., DeVivo, M., Dingus, J., Harry, A., Li, J., Sui, J., Carty, 
D.J., Blank, J.L., Exton, J.H., Stoffel, R.H., Inglese, J., Lefko-
witz, R.J., Logothetis, D.E., Hildebrandt, J.D., and Iyengar, R. 
(1995) Science 268, 1166-1169. 
Hawes, B.E., Touhara, K., Kurose, H., Lefkowitz, R.J. and Ing-
lese, J. (1994) J. Biol. Chem. 269, 29825-29830. 
Xu, J., Wu, D., Slepak, V.Z. and Simon, M.I. (1995) Proc. Natl. 
Acad. Sei. USA 92, 2086-2090. 
Miles, M.F., Barhite, S., Sganga, M. and Elliott, M. (1993) Proc. 
Natl. Acad. Sei. USA 90, 10831-10835. 
Schröder, S. and Lohse, M.J.L. (1996) Proc. Natl. Acad. Sei. 
USA 93, 2100-2104. 
Sternweis, P.C. and Robishaw, J.D. (1984) J. Biol. Chem. 259, 
13806-13813. 
Söhlemann, P., Hekman, M., Elce, J.S., Buchen, C. and Lohse, 
M.J. (1993) FEBS Lett. 324, 59-62. 
Bradford, M.M. (1976) Anal. Biochem. 72, 248-254. 
Hekman, M., Holzhöfer, A., Gierschik, P., Im, M.J., Jakobs, 
K.H., Pfeuffer, T. and Helmreich, E.J.M. (1987) Eur. J. Biochem. 
169, 431^139. 
Lohse, M.J., Andexinger, S., Pitcher, J., Trukawinski, S., Codina, 
J., Faure, J-P., Caron, M.G. and Lefkowitz, R.J. (1992) J. Biol. 
Chem. 267, 8558-8564. 
Wilden, U. and Kühn, H. (1982) Biochemistry 21, 3014-3022. 
Lohse, M.J., Klotz, K-N. and Schwabe, U. (1986) Mol. Pharma-
col. 30, 403^109. 
Higashijima, T., Ferguson, K.M., Sternweis, P., Smigel, M. and 
Gilman, A.G. (1987) J. Biol. Chem. 262, 762-766. 
Gaudet, R., Böhm, A. and Sigler, P.B. (1996) Cell 87, 577-588. 
